62 security-"https:" "https:" "https:" "https:" "U.S" research jobs at University of Oxford
Sort by
Refine Your Search
-
operando data related to battery degradation and safety. You will develop and implement advanced deep learning models to analyse multi-modal operando data from accelerated stress testing, with the aim
-
Philanthropy and is fixed-term until 31 Dec 2027. A further extension to this would be based on funding availability. You will conduct hands-on empirical research in multi-agent security and agentic AI security
-
develop foundational security theory for agentic and multi-agent AI systems, as part of our research programme in multi-agent security. You will build formal models of security-relevant behaviour in
-
spectroscopy methods (Operando XPS/XAS, Hard XPS) to probe the interfacial reactions occurring in Li-ion batteries. Further information about the research group can be found at: https://emi.materials.ox.ac.uk
-
). The successful candidate will work in Dr Ruxandra Dafinca’s team ( https://www.ndcn.ox.ac.uk/team/ruxandra-dafinca ) in a stimulating environment as part of the Nuffield Department of Clinical Neurosciences and
-
pages on the application process at https://www.jobs.ox.ac.uk/application-process The closing date for applications is 12:00 midday on 29 April 2026.
-
) Further information can be found at http://www.eng.ox.ac.uk/jobs/home Only online applications received before midday on 8 May 2026 can be considered. You will be required to upload a covering letter
-
guidance at https://www.jobs.ox.ac.uk/cv-and-supporting-statement. Any technical questions related to this vacancy can be sent to: recruit@ouce.ox.ac.uk The closing date for applications is 12.00 noon on 7
-
on “Active exploration of iridescence and gloss”. The ESR will join the EXPLORA consortium (https://explora-network.github.io/web/index.html ), which comprises 12 academic institutions across multiple European
-
clinical trial of investigational medicinal products testing the efficacy and safety of immunotherapy (IVIG and rituximab) in people with acute psychosis and anti-neuronal membrane antibodies What We Offer